Vivani Medical (VANI) 10-Q 13 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 10, 2020
Document Information [Line Items]
Entity Registrant Name	SECOND SIGHT MEDICAL PRODUCTS INC
Entity Central Index Key	0001266806
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity File Number	001-36747
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	02-0692322
Entity Address, Address Line One	12744 San Fernando Road
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Sylmar
Entity Address, Postal Zip Code	91342
City Area Code	818
Local Phone Number	833-5000
Entity Address, State or Province	CA
Entity Common Stock, Shares Outstanding		23,118,233
Document Quarterly Report	true
Document Transition Report	false
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	EYES
Security Exchange Name	NASDAQ
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	EYESW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 3,505	$ 11,327
Accounts receivable, net		455
Inventories, net		1,029
Assets held-for-sale	400
Prepaid expenses and other current assets	676	299
Total current assets	4,581	13,110
Property and equipment, net	212	1,122
Right-of-use assets		2,342
Deposits and other assets	12	25
Total assets	4,805	16,599
Current liabilities:
Accounts payable	517	1,093
Accrued expenses	1,023	1,889
Accrued compensation expense	330	2,698
Accrued clinical trial expenses	517	707
Current operating lease liabilities		237
Contract liabilities	335	335
Total current liabilities	2,722	6,959
Long term operating lease liabilities		2,365
Total liabilities	2,722	9,324
Commitments and contingencies
Stockholders’ equity:
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 23,118 and 15,643 as of June 30, 2020 and December 31, 2019, respectively	270,126	264,008
Additional paid-in capital	49,260	48,613
Accumulated other comprehensive loss	(533)	(562)
Accumulated deficit	(316,770)	(304,784)
Total stockholders’ equity	2,083	7,275
Total liabilities and stockholders’ equity	$ 4,805	$ 16,599

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, no par value (in dollars per share)
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, no par value (in dollars per share)
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	23,118,000	15,643,000
Common stock, shares outstanding (in shares)	23,118,000	15,643,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net sales		$ 1,282		$ 2,410
Cost of sales		933		1,664
Gross profit		349		746
Operating expenses:
Research and development, net of grants	$ 323	3,436	$ 4,210	5,619
Clinical and regulatory, net of grants	429	536	1,343	1,542
Selling and marketing		1,689	701	3,792
General and administrative	1,516	2,256	3,537	4,705
Restructuring charges	848	873	2,229	3,297
Total operating expenses	3,116	8,790	12,020	18,955
Loss from operations	(3,116)	(8,441)	(12,020)	(18,209)
Interest income	16	1	34	69
Net loss	$ (3,100)	$ (8,440)	$ (11,986)	$ (18,140)
Net loss per common share – basic and diluted	$ (0.15)	$ (0.56)	$ (0.67)	$ (1.28)
Weighted average common shares outstanding – basic and diluted	20,337	15,542	17,993	13,816

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (3,100)	$ (8,440)	$ (11,986)	$ (18,140)
Other comprehensive income (loss):
Foreign currency translation adjustments	10	9	29	1
Comprehensive loss	$ (3,090)	$ (8,431)	$ (11,957)	$ (18,139)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) - USD ($) $ in Thousands	Total	Employee Stock Purchase Plan [Member]	Common Stock [Member]	Common Stock [Member]Employee Stock Purchase Plan [Member]	Accumulated Other Comprehensive Loss [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance beginning at Dec. 31, 2018	$ 3,084		$ 229,019		$ (575)	$ 44,111	$ (269,471)
Balance beginning (in shares) at Dec. 31, 2018			9,542,000
Adoption of ASC Topic 842-Leases (see note 2) at Dec. 31, 2018	(144)						(144)
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs	34,399		$ 34,399
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs (in shares)			5,976,000
Release of restricted stock units (shares)			6,000
Warrants modification (see note 7)						1,577	(1,577)
Stock-based compensation expense	898					898
Net loss	(9,700)						(9,700)
Foreign currency translation adjustment	(8)				(8)
Balance ending at Mar. 31, 2019	28,529		$ 263,418		(583)	46,586	(280,892)
Balance ending (in shares) at Mar. 31, 2019			15,524,000
Balance beginning at Dec. 31, 2018	3,084		$ 229,019		(575)	44,111	(269,471)
Balance beginning (in shares) at Dec. 31, 2018			9,542,000
Adoption of ASC Topic 842-Leases (see note 2) at Dec. 31, 2018	(144)						(144)
Net loss	(18,140)
Foreign currency translation adjustment	1
Balance ending at Jun. 30, 2019	21,195		$ 263,656		(574)	47,445	(289,332)
Balance ending (in shares) at Jun. 30, 2019			15,573,000
Balance beginning at Mar. 31, 2019	28,529		$ 263,418		(583)	46,586	(280,892)
Balance beginning (in shares) at Mar. 31, 2019			15,524,000
Issuance of common stock in connection with employee stock purchase plan	238		$ 238
Issuance of common stock in connection with Employee Stock Purchase Plan (in shares)			47,000
Release of restricted stock units (shares)			2,000
Stock-based compensation expense	859					859
Net loss	(8,440)						(8,440)
Foreign currency translation adjustment	9				9
Balance ending at Jun. 30, 2019	21,195		$ 263,656		(574)	47,445	(289,332)
Balance ending (in shares) at Jun. 30, 2019			15,573,000
Balance beginning at Dec. 31, 2019	$ 7,275		$ 264,008		(562)	48,613	(304,784)
Balance beginning (in shares) at Dec. 31, 2019	15,643,000		15,643,000
Repurchase of fractional shares in connection with reverse stock split	$ (11)		$ (11)
Repurchase of Fractional Shares In Connection With Reverse Stock Split (In Shares)			(2,000)
Issuance of shares of common stock	6		$ 6
Issuance of shares of common stock, Shares			1,000
Release of restricted stock units (shares)			15,000
Stock-based compensation expense	279					279
Net loss	(8,886)						(8,886)
Foreign currency translation adjustment	19				19
Balance ending at Mar. 31, 2020	(1,318)		$ 264,003		(543)	48,892	(313,670)
Balance ending (in shares) at Mar. 31, 2020			15,657,000
Balance beginning at Dec. 31, 2019	$ 7,275		$ 264,008		(562)	48,613	(304,784)
Balance beginning (in shares) at Dec. 31, 2019	15,643,000		15,643,000
Net loss	$ (11,986)
Foreign currency translation adjustment	29
Balance ending at Jun. 30, 2020	$ 2,083		$ 270,126		(533)	49,260	(316,770)
Balance ending (in shares) at Jun. 30, 2020	23,118,000		23,118,000
Balance beginning at Mar. 31, 2020	$ (1,318)		$ 264,003		(543)	48,892	(313,670)
Balance beginning (in shares) at Mar. 31, 2020			15,657,000
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs	6,673		$ 6,393			280
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs (in shares)			7,500,000
Repurchase of ESPP shares as part of a rescission offer		$ (270)		$ (270)
Repurchase of ESPP shares as part of a rescission offer (in shares)				(39,000)
Stock-based compensation expense	88					88
Net loss	(3,100)						(3,100)
Foreign currency translation adjustment	10				10
Balance ending at Jun. 30, 2020	$ 2,083		$ 270,126		$ (533)	$ 49,260	$ (316,770)
Balance ending (in shares) at Jun. 30, 2020	23,118,000		23,118,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (11,986)	$ (18,140)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	126	196
Stock-based compensation	367	1,757
Non-cash lease expense	3	10
Inventory reserve		(446)
Restructuring charges-inventory and fixed asset impairment	1,115	2,587
Changes in operating assets and liabilities:
Accounts receivable	461	(122)
Inventories	(144)	(364)
Prepaid expenses and other assets	(364)	585
Accounts payable	(1,019)	(49)
Accrued expenses	108	192
Accrued compensation expenses	(2,369)	(483)
Accrued clinical trial expenses	(189)	105
Contract liabilities		387
Net cash used in operating activities	(13,891)	(13,785)
Cash flows from investing activities:
Purchases of property and equipment	(331)	(164)
Net cash used in investing activities	(331)	(164)
Cash flows from financing activities:
Net proceeds from sale of common stock and/or warrants	6,679	34,399
Proceeds from employee stock purchase plan		238
Repurchase of ESPP shares and fractional shares in connection with reverse stock split	(281)
Net cash provided by financing activities	6,398	34,637
Effect of exchange rate changes on cash and cash equivalents	2	2
Cash and cash equivalents:
Net increase (decrease)	(7,822)	20,690
Balance at beginning of period	11,327	4,471
Balance at end of period	3,505	$ 25,161
Non-cash financing activities:
Fair value of warrants issued in connection with issuance of common stock	$ 280

Organization and Business Opera

Organization and Business Operations	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Second Sight Medical Products, Inc. (“Second Sight,” “we,” “us,” or “the Company”) was incorporated in the State of California in 2003. Second Sight develops implantable visual prosthetics to potentially enable blind individuals to achieve greater independence. In 2007, Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials and sales and marketing in Europe, the Middle East and Asia-Pacific, and more recently for the research of future technologies. As the laws of Switzerland require at least two corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is 99.5% owned directly by us and 0.5% owned by an executive of Second Sight as of June 30, 2020. Accordingly, Second Sight Medical Products (Switzerland) Sàrl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented. In June 2020, we commenced a process to dissolve our Swiss subsidiary which is expected to take approximately one year. We are currently developing the Orion ® Our first commercially approved product, the Argus ® In March 2020, we were severely adversely impacted by the COVID-19 pandemic and its related effects on our ability to finance our planned activities. As a result, we significantly reduced our staff and expenses and conserved liquidity as we continue operations and explore strategic options. These options include securing additional funding and exploring business alternatives that may include partnering, acquiring, investing in or combining with businesses that may or may not be in a related industry. No assurances can be given that any of these initiatives will occur. Liquidity and Going Concern From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. Funding of our business since 2017 has been primarily provided by: • Issuance of shares of common stock on May 5, 2020 which provided net proceeds of approximately $6.7 million. • Issuance of common stock and warrants in a Rights Offering in February 2019 which provided $34.4 million of net cash proceeds • Issuances of common stock through our At Market Issuance Sales Agreement during the fourth quarter of 2019 which provided $0.1 million of net cash proceeds • Issuances of common stock through our At Market Issuance Sales Agreement during the first quarter of 2018, which provided $4.0 million of net cash proceeds • Issuances of common stock via stock purchase agreements in May, August, October and December 2018, which provided net cash proceeds of $22.0 million • Revenue of $3.4 million and $6.9 million, for the years ended December 31, 2019 and 2018, respectively, generated by sales of our Argus II product On May 5, 2020, we closed our underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate net proceeds of approximately $6.7 million. We received an award for $1.6 million grant (with the intent to fund $6.4 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis” that commenced in January 2018. Our second year grant was recently approved under this grant. As of June 30, 2020 we recorded $0.3 million of deferred grant costs which will be offset with the related grant funds when received. During the six months ended June 30, 2020, we received a total of $0.4 million of grant funds primarily from this grant. On September 17, 2019, we received a $2.4 million, four-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (“SLAM”). This grant involves a joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), and is intended to speed the integration of SLAM into future generations of Orion. The goal is to give Orion users the ability to localize objects and navigate landmarks in unfamiliar surroundings in real time. APL is the primary recipient of the grant. We have suspended our activities on the project until we clarify our future plans. In a rights offering completed on February 22, 2019, we sold approximately 5,976,000 million units, each priced at $5.792 for net proceeds of approximately $34.4 million. Each unit consisted of one share and one immediately exercisable warrant having an exercise price of $11.76 per share. Entities controlled by Gregg Williams, our Chairman of the Board of Directors, acquired approximately 5,180,000 million units in the offering for an aggregate investment of approximately $30 million. In November 2017, we entered into an At Market Issuance Sales Agreement (“Sales Agreement”) with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we offered and sold, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During January and February 2018, we sold approximately 278,000 shares of common stock which provided net proceeds of $4.0 million under the Sales Agreement. Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with no revenue that is developing a novel medical device, including limitations on our operating capital resources. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. As more fully described in Note 11, we have been notified by the Nasdaq stock market regarding our non-compliance with the continued listing requirement on the Nasdaq capital market pursuant to its listing rules, and therefore we could be subject to delisting if we do not regain compliance within the compliance period (or the compliance period as may be extended). Based upon our current plans we do not have sufficient funds to support our operations for the next 12 months from the date of issuance of these financial statements. Accordingly, these and other related factors raise substantial doubt about our ability to continue as a going concern. We anticipate that we will seek to additionally fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. However, we may be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or any other approved product candidates, or we may be unable to maintain our current limited operations, maintain our current organization and reduced employee base or otherwise capitalize on our business opportunities, as desired, which could materially and adversely affect our business, financial condition and results of operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Our independent registered public accounting firm, in its report on our 2019 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern.

Basis of Presentation, Signific

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2020
Disclosure Text Block [Abstract]
Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2019, contained in our Annual Report on Form 10-K filed with the SEC on March 19, 2020. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period. Reverse Stok Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020. The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted. Significant Accounting Policies Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market. Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform and suspend production of Argus, we recorded impairment charges of $2.6 million related to inventory of Argus II in the six months ended June 30, 2019. As part of this transition we commenced a corporate restructuring plan to focus on development of Orion and other key research projects. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $0.5 million and $0.7 million to our fixed assets used primarily for Argus activities. We also incurred $1.0 million in severance payments and other costs associated with the wind down, all of which were substantially paid by June 30, 2020. We continue to advance the development of our Orion technology and are exploring various strategic options, however we cannot assure that any of these endeavors will yield satisfactory results or that we will be able to maintain our operations. Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019. Recently Issued Accounting Pronouncements We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Concentration of Risk

Concentration of Risk	6 Months Ended
	Jun. 30, 2020
Risks And Uncertainties [Abstract]
Concentration of Risk	3. Concentration of Risk Credit Risk Financial instruments that subject us to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. We maintain cash and money market funds with financial institutions that we deem reputable. We extended differing levels of credit to our customers, and typically did not require collateral. Customer Concentration The following tables provide information about disaggregated revenue by service type, customer and geographical market. The following table shows our revenues by customer type during the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Direct customers $ — $ 1,006 $ — $ 1,952 Indirect customers (distributors) — 276 — 458 Total $ — $ 1,282 $ — $ 2,410 During the three and six months ended June 30, 2020 and 2019, the following customers each comprised greater than 10% of our total revenues : Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Customer 1 — % 26 % — % 14 % Customer 2 — % 21 % — % 11 % Customer 3 — % 13 % — % 14 % Customer 4 — % 13 % — % 7 % Customer 5 — % 10 % — % 16 % Customer 6 — % 10 % — % 10 % As of June 30, 2020 and December 31, 2019, the following customers each comprised greater than 10% of our total accounts receivable: June 30, 2020 December 31, 2019 Customer 1 — % 35 % Customer 2 — % 33 % Customer 3 — % 32 % Geographic Concentration During the three and six months ended June 30, 2020 and 2019, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following : Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 United States — % 68 % — % 65 % China — % 13 % — % 7 % Italy — % 10 % — % 16 % Foreign Operations The accompanying condensed consolidated financial statements as of June 30, 2020 and December 31, 2019 include gross assets amounting to $0.9 million

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. Cash equivalents, which includes money market funds, are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level 1 inputs. Assets measured at fair value on a recurring basis are as follows (in thousands): Total Level 1 Level 2 Level 3 June 30, 2020 (unaudited): Money market funds $ 3,437 $ 3,437 $ — $ — December 31, 2019: Money market funds $ 11,307 $ 11,307 $ — $ —

Selected Balance Sheet Detail

Selected Balance Sheet Detail	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Selected Balance Sheet Detail	5. Selected Balance Sheet Detail Inventories, net Inventories consisted of the following (in thousands): June 30, December 31, 2020 2019 Raw materials $ 741 $ 803 Work in process 1,461 1,716 Finished goods 1,290 2,069 3,492 4,588 Allowance for excess and obsolete inventory and impairment charge (3,492 ) (3,559 ) Inventories, net $ — $ 1,029 We recorded $2.6 million as an impairment charge during the six months ended June 30, 2019, related to our plans to suspend Argus II production. We recorded further impairment charges to our inventory of $0.5 million in the first six months of 2020. Additionally, finished goods inventory amounting to approximately $0.4 million that we expect to use for our future warranty claims has been offset with the warranty accrual which is included in accrued expenses. Property and equipment Property and equipment consisted of the following (in thousands): June 30, December 31, 2020 2019 Laboratory equipment $ 584 $ 2,724 Computer hardware and software 69 1,672 Leasehold improvements — 304 Furniture, fixtures and equipment — 78 653 4,778 Accumulated depreciation and amortization (441 ) (3,656 ) Property and equipment, net $ 212 $ 1,122 As a result of our decision to cease marketing of Argus II we recorded an impairment of $0.7 million related to our fixed assets used primarily for Argus activities. We have additionally reclassified $0.4 million as assets held-for-sale which represents the estimated fair value of fixed assets that we sold. Proceeds from the sales which were received in July 2020 approximated the estimated recorded fair value of assets held-for-sale at June 30, 2020. Contract Liabilities Contract liabilities consisted of the following (in thousands): Beginning balance as of December 31, 2019 $ 335 Consideration received in advance of revenue recognition — Revenue recognized — Ending balance as of June 30, 2020 $ 335 Product Warranties A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended June 30, 2020 is presented below: Beginning balance as of December 31, 2019 $ 1,575 Additions — Settlements (419) Adjustments and other — Total 1,156 Less: Finished goods inventory expected to be used for future warranty claims (399) Ending balance as of June 30, 2020 $ 757 Allowance for Doubtful Accounts Allowance for doubtful accounts consisted of the following (in thousands): Beginning balance as of December 31, 2019 $ 117 Additions — Write-offs (117) Ending balance as of June 30, 2020 $ — Right-of-use assets and operating lease liabilities We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate of 10% based on the information available at commencement date in determining the present value of lease payments. On May 18, 2020 we entered into a Letter Agreement with Sylmar Biomedical Park, LLC (the “Landlord”), pursuant to which the parties agreed to accelerate the expiration dates of our existing leases (the “Leases”), to a date not later than June 18, 2020 (“Accelerated Termination Date”). We agreed to pay the Landlord (i) $210,730 to bring the Leases current (the “Owed Rent”) and to remit (ii) a one-time early termination fee in the amount of $150,000 (the “Early Termination Amount”). Prior to the early termination agreed in this letter we were obligated to pay aggregate base rent of approximately $0.9 million and common area maintenance expenses for the term remaining under the Leases through the respective expiration dates in February 2022 and April 2023. The Landlord acknowledged that as of the date of the Letter Agreement the Owed Rent and the Early Termination Amount constituted all amounts owing to the Landlord under the Leases. On July 7, 2020, we entered into a lease with Sylmar Biomedical Park, LLC, to lease a smaller portion of our present facility. The new lease allows us to significantly reduce our rent while maintaining operations and our current address. The term of the lease is from June 16, 2020 until December 31, 2020 and automatically renews monthly thereafter unless terminated by either party with 30 day notice. The monthly rent is $16,000 inclusive of a proportionate share of the building’s maintenance cost. Assets Classification December Non-current assets Right-of-use assets $ 2,342 Liabilities Current Current operating lease liabilities $ 237 Long term Long term operating lease liabilities $ 2,365 The components of lease expense for the three and six months ended June 30, 2020 and 2019 were as follows (unaudited): Three Months Ended June 30, Six Months Ended June 30, Lease expense : 2020 2019 2020 2019 Operating lease expense $ 106 $ 123 $ 229 $ 246 Short-term expense — — — — Total lease expense $ 106 $ 123 $ 229 $ 246 Cash paid for lease amounts included in the measurement of lease liabilities amounted to $227,000 and $237,000, respectively, during the six months ended June 30, 2020 and 2019.

Equity Securities

Equity Securities	6 Months Ended
	Jun. 30, 2020
Stockholders Equity Note [Abstract]
Equity Securities	6. Equity Securities Increase in Authorized Shares of Common Stock On June 4, 2019, our shareholders approved an amendment to our restated articles of incorporation increasing our authorized no par value shares of common stock from 200 million to 300 million shares. Potentially Dilutive Common Stock Equivalents As of June 30, 2020 and 2019, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands). June 30, 2020 2019 Common stock warrants issued to underwriters 375 100 Common stock warrants issued in connection with March 2017 rights offering 1,706 1,706 Common stock warrants issued in connection with February 2019 rights offering 5,976 5,976 Common stock options 304 1,115 Restricted stock units 8 62 Employee stock purchase plan — 56 8,369 9,015

Warrants

Warrants	6 Months Ended
	Jun. 30, 2020
Warrants And Rights Note Disclosure [Abstract]
Warrants	7. Warrants On May 5, 2020, we closed our underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate net proceeds of approximately $6.7 million. Direct cost of this offering consisted of an 8.5% underwriting fee and reimbursable expenses of $90,000 and other costs incurred by us of $100,000. Also, for cash consideration of $100, we granted to the underwriters warrants to purchase 375,000 shares of the Company’s common stock at an exercise price of $1.25 per share, which was 25 percent above the offering price to the investors. The warrant is exercisable, in whole or in part, for a period commencing 180 days after the effective date of the underwriting agreement (April 30, 2020) and ending on the fifth anniversary date of the effective date of the underwriting agreement. he fair value of these warrants, calculated using the Black-Scholes option-pricing model, was determined to be $280,000 ($0.75 per share) using the following assumptions: expected term of 5.0 years, volatility of 94.0%, risk-free interest rate of 0.67% and expected dividend rate of 0.0%. The fair value of these warrants reduced the amounts included in common stock from the offering and were offset by an increase in additional paid in capital. On February 22, 2019, we completed a registered rights offering to existing stockholders in which we sold approximately 5,976,000 units at $5.792 per unit, which was the adjusted closing price of our common stock on that date. Each Unit consisted of a share of our common stock and a warrant to purchase an additional share of our stock for $11.76. The warrants had a five-year life and trade on Nasdaq under the symbol EYESW. On March 6, 2017, we completed a registered rights offering to existing stockholders in which we sold approximately 1,706,000 units at $11.76 per unit, which was the adjusted closing price of our common stock on that date. Each unit consisted of a share of our common stock and a warrant to purchase an additional share of our stock for $11.76. The warrants have a five-year life and have been approved for trading on Nasdaq under the symbol EYESW. As of June 30, 2020, 632 of the warrants associated with the rights offering had been exercised. We extended the term of 1.7 million warrants issued in our March 2017 rights offering by approximately two years effective as of February 15, 2019 as part of our February 2019 rights offering. We determined the fair value of the March 2017 Warrants immediately before and after the modification. The fair value of the March 2017 Warrants after the modification was increased by approximately $1.6 million, resulting in an accounting adjustment to additional paid-in capital and accumulated deficit in the consolidated statements of shareholders’ equity. The assumptions used in the determination of fair value of the warrants before and after the extension included a risk free interest rate of 2.50% and 2.49%, expected volatility of 81% and 82%, and expected lives of 3.08 years and 5.08 years, respectively and 0% dividend yields for both. A summary of warrants activity for the six months ended June 30, 2020 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2019 7,682 $ 11.76 4.21 Issued 375 1.25 4.85 Exercised — Forfeited or expired — Warrants outstanding as of June 30, 2020 8,057 $ 11.27 3.76 Warrants exercisable as of June 30, 2020 8,057 $ 11.27 3.76 The warrants outstanding as of June 30, 2020 had no intrinsic value.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the six months ended June 30, 2020 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Options outstanding as of December 31, 2019 984 $ 21.78 7.70 Granted 206 $ 5.98 Exercised — $ Forfeited or expired (886 ) $ 20.50 Options outstanding as of June 30, 2020 304 $ 14.82 8.05 Options exercisable as of June 30, 2020 181 $ 18.90 7.56 The estimated aggregate intrinsic value of stock options exercisable as of June 30, 2020 was zero. As of June 30, 2020, there was $0.7 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 2.76 years. During the six months ended June 30, 2020, we granted stock options to purchase 205,701 shares of common stock to certain employees. The options are exercisable for a period of ten years from the date of grant at $5.98 During the three and six months ended June 30, 2020, approximately 586,000 and 886,000 options were cancelled or expired resulting in a reduction of stock option expense of approximately $88,000 and $255,000, respectively. The following table summarizes restricted stock unit (“RSU”) activity for the six months ended June 30, 2020 (in thousands, except per share data): Number of Shares Weighted Average Grant Date Fair Value Per Share Outstanding as of December 31, 2019 61 $ 5.92 Awarded — — Vested and released (15 ) 5.92 Forfeited/canceled (38 ) 5.92 Outstanding as of June 30, 2020 8 $ 5.92 As of June 30, 2020, there was $40,000 of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 2.64 years. We adopted an employee stock purchase plan in June 2015 for all eligible employees. At June 30, 2020 the available number of shares that may be issued under the plan is 77,031. We completed our offer to rescind certain purchases of shares under our ESPP plan on May 27, 2020. We voluntarily offered to rescind the sale of shares of our common stock to employees who purchased those shares under the ESPP and to reimburse any losses upon the sale of our shares of our common stock for certain purchase periods because these shares may not have been exempt from registration under the Securities Act of 1933. The rescission of these share purchases resulted in the repurchase and cancelation of 39,467 shares of our common stock. The total cost for the repurchase of these shares and the reimbursement of any losses from the sale of such shares totaled approximately $270,000. Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three and six months ended June 30, 2020 and 2019 was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Cost of sales $ — $ 43 $ — $ 90 Research and development 7 134 109 321 Clinical and regulatory 12 31 27 65 Selling and marketing — 131 41 261 General and administrative 69 520 190 1,020 Total $ 88 $ 859 $ 367 $ 1,757

Risk and Uncertainties

Risk and Uncertainties	6 Months Ended
	Jun. 30, 2020
Risks And Uncertainties [Abstract]
Risk and Uncertainties	9. Risk and Uncertainties In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread globally. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, most states in the U.S., including California, where we are headquartered, have declared a state of emergency. The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. In accordance with local and state guidelines regarding the COVID-19 pandemic, we are requiring all of our employees to work remotely unless they cannot perform their essential functions remotely, and have also suspended all non-essential travel for our employees. While a significant number of our employees may be accustomed to working remotely or working with other remote employees, much of our workforce has not historically been remote. Although we continue to monitor the situation and may adjust our current policies as more information and public health guidance becomes available, temporarily suspending travel and restricting the ability to do business in person may create operational or other challenges, any of which could harm our business, financial condition and results of operations.  In addition, our clinical trials have been affected by the COVID-19 outbreak. Patient visits in ongoing clinical trials have been delayed, for example, due to prioritization of hospital resources toward the COVID-19 outbreak, travel restrictions imposed by governments, and the inability to access sites for initiation and monitoring. For example, scheduled patient visits to our clinical sites at UCLA and Baylor were temporarily put on hold due to COVID-19 and we are in the process of planning to resume patient visits with the sites. Although regularly scheduled visits are on hold due to the sites continue to see patients if needed for any potential medical issues that may arise including any suspected adverse events. COVID-19 has directly and indirectly adversely affected Second Sight and will likely continue to do so for an uncertain period of time. In March and April 2020 we laid off a substantial majority of our employees as a result of COVID-19 and an inability to obtain financing. We retain approximately 10 of our employees to oversee current operations. The cumulative effects of COVID-19 on the Company cannot be predicted at this time, but could include, without limitation: • inability to meet warranty obligations for our Argus II products; • reputational damages of the Company and its products; • inability to raise additional funds to finance and continue our operations; • inability to maintain adequate office laboratory facilities; • inability to retain and hire experienced personnel; • inability to finalize our plan for and enroll patients into our proposed pivotal clinical trial; • material delays or inability to complete development and commercialization of Orion; • inability to satisfy Nasdaq’s continued listing requirements and possible delisting; and • other uncertain events that may have negative impact on our operations.

Litigation, Claims and Assessme

Litigation, Claims and Assessments	6 Months Ended
	Jun. 30, 2020
Disclosure Text Block [Abstract]
Litigation, Claims and Assessments	10. Litigation, Claims and Assessments Ten oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by us. We have filed one opposition that is currently pending in the European Patent Office challenging the validity of a patent owned by Pixium Vision. The outcome of the challenges are not certain, however, if successful, they may affect our ability to block competitors from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations. By letters received on June 23, 2020 and July 21, 2020 counsel for a participant in the Orion Early Feasibility Study has alleged claims against the Company for breach of contract, breach of the implied covenant of good faith and fair dealing, negligent misrepresentation, promissory estoppel and negligent infliction of emotional distress. Counsel in addition has alleged that Second Sight has violated the protocol established by the FDA for good clinical practice within this industry. As full compensation for damages arising from these claims the Company was presented with a demand for payment of $3,000,000. The Company believes that the claims asserted are without merit. Although the Company does not believe a lawsuit will be filed imminently, the claim is in the early stage and no assurance can be given that this matter will not result in litigation. To the extent a lawsuit is filed, the Company intends to vigorously defend it. We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations, however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events Nasdaq Letter from Nasdaq dated July 23, 2020 or in two of the three most recently completed, fiscal years, respectively In the event we do not regain compliance with the Rule prior to the expiration of the compliance period, we will receive written notification that our securities are subject to delisting. At that time, we may appeal the delisting determination to a Nasdaq Hearings Panel. In the event we do not regain compliance with the Rule prior to the expiration of the compliance period, we will receive written notification that our securities are subject to delisting. At that time, we may appeal the delisting determination to a Nasdaq Hearings Panel. Letter from Nasdaq dated July 21, 2020 On July 21, 2020, Nasdaq notified us, based on our submitted information that the board of directors had appointed an independent director to our compensation committee, that we currently comply with Rule 5605(d)(2) (the “Rule”), and this matter is now closed. As previously disclosed prior to that remediation, Nasdaq had notified us on June 2, 2020 that we did not comply with the compensation committee requirement for continued listing on Nasdaq set forth in the Rule. Separately from the foregoing, Nasdaq had notified us on July 15, 2020 that we again qualified for a cure period to meet listing rules brought into question due to changes in board of directors. We previously reported in Forms 8-K filed with the SEC regarding letters from Nasdaq dated April 15, 2020, June 1, 2020, and June 2, 2020. As previously disclosed, Nasdaq notified us on April 15, 2020, after the appointment of Matthew Pfeffer, one of our then independent directors, as our acting Chief Executive Officer effective March 27, 2020, that we no longer complied with Nasdaq’s independent director and audit committee forth in Listing Rule 5605 (the “Listing Rules”). Our board of directors has concluded that our non-executive Chair, Gregg Williams, meets the criteria of an independent director and has appointed Mr. Williams to be a member of the Audit Committee as of June 22, 2020, as a result of which the Company has only one vacancy on its board and committees. In the July 15, 2020 letter, Nasdaq acknowledged our conclusion regarding Mr. Williams’ independent director status and appointment to the Audit Committee. As a result, Nasdaq confirmed that we again are eligible for the cure period provided in Nasdaq’s Listing Rules. As such, Nasdaq reiterated that consistent with Listing Rules 5605(b)(1)(A) and 5605(c)(4), our cure period to regain compliance is as follows: • until the earlier of the Company’s next annual shareholders’ meeting or March 27, 2021; or • if the next annual shareholders’ meeting is held before September 23, 2020, then the Company must evidence compliance no later than September 23, 2020. Nasdaq requires us to submit documentation, including biographies of any new directors, evidencing compliance with the rules no later than as described above. If we do not regain compliance by the dates set forth above, Nasdaq will provide us written notification that our securities will be delisted, at which time we may appeal the delisting determination to a Nasdaq Hearing Panel.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Disclosure Text Block [Abstract]
Significant Accounting Policies	Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2019, contained in our Annual Report on Form 10-K filed with the SEC on March 19, 2020. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.
Reverse Stok Split	Reverse Stok Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020. The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted.
Segment Reporting	Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market. Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform and suspend production of Argus, we recorded impairment charges of $2.6 million related to inventory of Argus II in the six months ended June 30, 2019. As part of this transition we commenced a corporate restructuring plan to focus on development of Orion and other key research projects. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $0.5 million and $0.7 million to our fixed assets used primarily for Argus activities. We also incurred $1.0 million in severance payments and other costs associated with the wind down, all of which were substantially paid by June 30, 2020. We continue to advance the development of our Orion technology and are exploring various strategic options, however we cannot assure that any of these endeavors will yield satisfactory results or that we will be able to maintain our operations. Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019.
Recent Accounting Pronouncements	Recently Issued Accounting Pronouncements We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Concentration of Risk (Tables)

Concentration of Risk (Tables)	6 Months Ended
	Jun. 30, 2020
Risks And Uncertainties [Abstract]
Schedules of Revenues by Customer Type	The following table shows our revenues by customer type during the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Direct customers $ — $ 1,006 $ — $ 1,952 Indirect customers (distributors) — 276 — 458 Total $ — $ 1,282 $ — $ 2,410
Schedule of Concentration of Risk	During the three and six months ended June 30, 2020 and 2019, the following customers each comprised greater than 10% of our total revenues : Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Customer 1 — % 26 % — % 14 % Customer 2 — % 21 % — % 11 % Customer 3 — % 13 % — % 14 % Customer 4 — % 13 % — % 7 % Customer 5 — % 10 % — % 16 % Customer 6 — % 10 % — % 10 % As of June 30, 2020 and December 31, 2019, the following customers each comprised greater than 10% of our total accounts receivable: June 30, 2020 December 31, 2019 Customer 1 — % 35 % Customer 2 — % 33 % Customer 3 — % 32 %
Schedule of Geographic Concentration of Risk in Revenue	During the three and six months ended June 30, 2020 and 2019, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following : Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 United States — % 68 % — % 65 % China — % 13 % — % 7 % Italy — % 10 % — % 16 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets Measured on Recurring Basis	Assets measured at fair value on a recurring basis are as follows (in thousands): Total Level 1 Level 2 Level 3 June 30, 2020 (unaudited): Money market funds $ 3,437 $ 3,437 $ — $ — December 31, 2019: Money market funds $ 11,307 $ 11,307 $ — $ —

Selected Balance Sheet Detail (

Selected Balance Sheet Detail (Tables)	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventories	Inventories consisted of the following (in thousands): June 30, December 31, 2020 2019 Raw materials $ 741 $ 803 Work in process 1,461 1,716 Finished goods 1,290 2,069 3,492 4,588 Allowance for excess and obsolete inventory and impairment charge (3,492 ) (3,559 ) Inventories, net $ — $ 1,029
Schedule of Property and Equipment	Property and equipment consisted of the following (in thousands): June 30, December 31, 2020 2019 Laboratory equipment $ 584 $ 2,724 Computer hardware and software 69 1,672 Leasehold improvements — 304 Furniture, fixtures and equipment — 78 653 4,778 Accumulated depreciation and amortization (441 ) (3,656 ) Property and equipment, net $ 212 $ 1,122
Schedule of Contract Liabilities	Contract liabilities consisted of the following (in thousands): Beginning balance as of December 31, 2019 $ 335 Consideration received in advance of revenue recognition — Revenue recognized — Ending balance as of June 30, 2020 $ 335
Schedule of Activity in the Company's Warranty Liabilities	A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended June 30, 2020 is presented below: Beginning balance as of December 31, 2019 $ 1,575 Additions — Settlements (419) Adjustments and other — Total 1,156 Less: Finished goods inventory expected to be used for future warranty claims (399) Ending balance as of June 30, 2020 $ 757
Schedule of Allowance for Doubtful Accounts	Allowance for doubtful accounts consisted of the following (in thousands): Beginning balance as of December 31, 2019 $ 117 Additions — Write-offs (117) Ending balance as of June 30, 2020 $ —
Schedule of Lease Assets and Liabilities	Assets Classification December Non-current assets Right-of-use assets $ 2,342 Liabilities Current Current operating lease liabilities $ 237 Long term Long term operating lease liabilities $ 2,365
Schedule of Lease Costs	The components of lease expense for the three and six months ended June 30, 2020 and 2019 were as follows (unaudited): Three Months Ended June 30, Six Months Ended June 30, Lease expense : 2020 2019 2020 2019 Operating lease expense $ 106 $ 123 $ 229 $ 246 Short-term expense — — — — Total lease expense $ 106 $ 123 $ 229 $ 246

Equity Securities (Tables)

Equity Securities (Tables)	6 Months Ended
	Jun. 30, 2020
Stockholders Equity Note [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	As of June 30, 2020 and 2019, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands). June 30, 2020 2019 Common stock warrants issued to underwriters 375 100 Common stock warrants issued in connection with March 2017 rights offering 1,706 1,706 Common stock warrants issued in connection with February 2019 rights offering 5,976 5,976 Common stock options 304 1,115 Restricted stock units 8 62 Employee stock purchase plan — 56 8,369 9,015

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Warrants And Rights Note Disclosure [Abstract]
Summary of Warrant Activity	A summary of warrants activity for the six months ended June 30, 2020 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2019 7,682 $ 11.76 4.21 Issued 375 1.25 4.85 Exercised — Forfeited or expired — Warrants outstanding as of June 30, 2020 8,057 $ 11.27 3.76 Warrants exercisable as of June 30, 2020 8,057 $ 11.27 3.76

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the six months ended June 30, 2020 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Options outstanding as of December 31, 2019 984 $ 21.78 7.70 Granted 206 $ 5.98 Exercised — $ Forfeited or expired (886 ) $ 20.50 Options outstanding as of June 30, 2020 304 $ 14.82 8.05 Options exercisable as of June 30, 2020 181 $ 18.90 7.56
Summary of Restricted Stock Unit (RSU) Activity	The following table summarizes restricted stock unit (“RSU”) activity for the six months ended June 30, 2020 (in thousands, except per share data): Number of Shares Weighted Average Grant Date Fair Value Per Share Outstanding as of December 31, 2019 61 $ 5.92 Awarded — — Vested and released (15 ) 5.92 Forfeited/canceled (38 ) 5.92 Outstanding as of June 30, 2020 8 $ 5.92
Stock-based Compensation Expense	Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three and six months ended June 30, 2020 and 2019 was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Cost of sales $ — $ 43 $ — $ 90 Research and development 7 134 109 321 Clinical and regulatory 12 31 27 65 Selling and marketing — 131 41 261 General and administrative 69 520 190 1,020 Total $ 88 $ 859 $ 367 $ 1,757

Organization and Business Ope_2

Organization and Business Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands

May 05, 2020

Sep. 17, 2019

Feb. 22, 2019

Mar. 06, 2017

Feb. 28, 2019

Feb. 28, 2018

Dec. 31, 2019

Jun. 30, 2019

Mar. 31, 2018

Jun. 30, 2020

Jun. 30, 2019

Dec. 31, 2019

Dec. 31, 2018

Organization And Business Operations [Line Items]

Net sales

$ 1,282

$ 2,410

$ 3,400

$ 6,900

Type of Revenue [Extensible List]

us-gaap:ProductMember

us-gaap:ProductMember

Deferred costs

$ 300

Received grant

$ 2,400

Grant received funding period

4 years

National Institutes of Health [Member]

Organization And Business Operations [Line Items]

Grant received funding

400

Grant [Member] | National Institutes of Health [Member]

Organization And Business Operations [Line Items]

Net sales

1,600

Grant received funding

$ 6,400

Right Offering [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 34,400

$ 34,400

Number of shares issued upon right offering

5,976,000

1,706,000

Share price (in dollars per share)

$ 5.792

$ 11.76

Exercise price of exercisable warrant

$ 11.76

At Market Issuance Sales Agreement [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 4,000

$ 100

$ 4,000

$ 100

Sale of Stock, commission paid to agents, percentage of gross proceeds

3.00%

Issuance of shares of common stock in connection with ATM, net of expenses (in shares)

278,000

17,000

Common Stock [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 6,700

Number of shares issued upon right offering

7,500,000

Share price (in dollars per share)

$ 1

Common Stock [Member] | Right Offering [Member]

Organization And Business Operations [Line Items]

Number of securities called by each warrant or right

1

Warrant [Member] | Right Offering [Member]

Organization And Business Operations [Line Items]

Number of securities called by each warrant or right

1

Entities Beneficially Owned by Mr. Gregg Williams [Member] | Right Offering [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 30,000

Number of shares issued upon right offering

5,180,000,000,000

Entities Beneficially Owned by Mr. Gregg Williams [Member] | Stock Purchase Agreement [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 22,000

Second Sight (Switzerland) Sarl [Member]

Organization And Business Operations [Line Items]

Noncontrolling interest, ownership percentage by parent

99.50%

Second Sight (Switzerland) Sarl [Member] | Executive Officer [Member]

Organization And Business Operations [Line Items]

Noncontrolling interest, ownership percentage by noncontrolling owners

0.50%

Summary of Significant Accounti

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Reverse stock split		1-for-8
Fixed Assets [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge		$ 0.4
Argus II Product [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge			$ 2.6
Argus II Product [Member] | Inventories
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge		$ 0.5
Argus II Product [Member] | Fixed Assets [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge	$ 0.7
Severance [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Restructuring charges, settle	$ 1

Concentration of Risk - Schedul

Concentration of Risk - Schedule of Revenues by Customer Type (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Concentration Risk [Line Items]
Revenue	$ 1,282	$ 2,410	$ 3,400	$ 6,900
Direct Customers [Member]
Concentration Risk [Line Items]
Revenue	1,006	1,952
Indirect Customers (Distributors) [Member]
Concentration Risk [Line Items]
Revenue	$ 276	$ 458

Concentration of Risk - Sched_2

Concentration of Risk - Schedule of Concentration of Risk (Details) - Customer Concentration Risk [Member]	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2019
Customer 1 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	26.00%	14.00%
Customer 1 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration			35.00%
Customer 2 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	21.00%	11.00%
Customer 2 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration			33.00%
Customer 3 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	13.00%	14.00%
Customer 3 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration			32.00%
Customer 4 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	13.00%	7.00%
Customer 5 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	10.00%	16.00%
Customer 6 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	10.00%	10.00%

Concentration of Risk - Sched_3

Concentration of Risk - Schedule of Geographic Concentration of Risk in Revenue (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
United States
Concentration Risk [Line Items]
Geographic concentration	68.00%	65.00%
China
Concentration Risk [Line Items]
Geographic concentration	13.00%	7.00%
Italy
Concentration Risk [Line Items]
Geographic concentration	10.00%	16.00%

Concentration of Risk - Additio

Concentration of Risk - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Concentration Risk [Line Items]
Assets	$ 4,805	$ 16,599
Second Sight (Switzerland) Sarl [Member]
Concentration Risk [Line Items]
Assets	900	$ 1,300
Reserves and allowances, net	$ 100

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value on a Recurring Basis (Details) - Money Market Funds [Member] - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Money market funds	$ 3,437	$ 11,307
Level 1 [Member]
Money market funds	$ 3,437	$ 11,307

Selected Balance Sheet Detail -

Selected Balance Sheet Detail - Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Raw materials	$ 741	$ 803
Work in process	1,461	1,716
Finished goods	1,290	2,069
Inventories, gross	3,492	4,588
Allowance for excess and obsolete inventory and impairment charge	$ (3,492)	(3,559)
Inventories, net		$ 1,029

Selected Balance Sheet Detail_2

Selected Balance Sheet Detail - Additional Information (Details) - USD ($)	Jul. 07, 2020	Jun. 30, 2020	May 18, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Product Information [Line Items]
Finished goods inventory expected to be used for future warranty claims				$ (399,000)
Estimated incremental borrowing rate				10.00%
Non-cash lease expense				$ 3,000	$ 10,000
Right-of-use assets						$ 2,342,000
Operating lease, liability, current						$ 237,000
Operating Lease, Payments				227,000	237,000
Sylmar Biomedical Park, LLC (the "Landlord") [Member]
Product Information [Line Items]
Termination date of the lease			Jun. 18, 2020
Non-cash lease expense			$ 210,730
Early lease termination fee			150,000
Payments for base rent subject to early termination			$ 900,000
Right-of-use assets		$ 2,300,000		2,300,000
Lease liability		2,400,000		2,400,000
Termination fee Paid		150,000		150,000
Operating lease right of use asset current		0		0
Operating lease, liability, current		0		0
Sylmar Biomedical Park, LLC (the "Landlord") [Member] | Subsequent Event [Member]
Product Information [Line Items]
Termination date of the lease	Dec. 31, 2020
Payment of monthly rent	$ 16,000
Argus II Product [Member]
Product Information [Line Items]
Impairment charge					$ 2,600,000
Other assets impairment charge				700,000
Inventory [Member]
Product Information [Line Items]
Impairment charge				500,000
Finished goods inventory expected to be used for future warranty claims				400,000
Fixed Assets [Member]
Product Information [Line Items]
Impairment charge				$ 400,000
Fixed Assets [Member] | Argus II Product [Member]
Product Information [Line Items]
Impairment charge		$ 700,000

Selected Balance Sheet Detail_3

Selected Balance Sheet Detail - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 653	$ 4,778
Accumulated depreciation and amortization	(441)	(3,656)
Property and equipment, net	212	1,122
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	584	2,724
Computer Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 69	1,672
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		304
Furniture, Fixtures and Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		$ 78

Selected Balance Sheet Detail_4

Selected Balance Sheet Detail - Schedule of Contract Liabilities (Details) $ in Thousands	Jun. 30, 2020USD ($)
Revenue From Contract With Customer [Abstract]
Beginning Balance	$ 335
Ending Balance	$ 335

Selected Balance Sheet Detail_5

Selected Balance Sheet Detail - Schedule of Activity in the Company's Warranty Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Beginning balance as of December 31, 2019	$ 1,575
Settlements	(419)
Total	1,156
Less: Finished goods inventory expected to be used for future warranty claims	(399)
Ending balance as of June 30, 2020	$ 757

Selected Balance Sheet Detail_6

Selected Balance Sheet Detail - Schedule of Allowance for Doubtful Accounts (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance as of December 31, 2019	$ 117
Write-offs	$ (117)

Selected Balance Sheet Detail_7

Selected Balance Sheet Detail - Schedule of Lease Assets and Liabilities (Details) $ in Thousands	Dec. 31, 2019USD ($)
ASSETS
Right-of-use assets	$ 2,342
Liabilities
Current operating lease liabilities	237
Long term operating lease liabilities	$ 2,365

Selected Balance Sheet Detail_8

Selected Balance Sheet Detail - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Lease expense:
Operating lease expense	$ 106	$ 123	$ 229	$ 246
Total lease expense	$ 106	$ 123	$ 229	$ 246

Equity Securities - Additional

Equity Securities - Additional Information (Details) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	Jun. 04, 2019	Mar. 31, 2019
Equity [Abstract]
Common stock, no par value (in dollars per share)
Common stock, shares authorized (in shares)	300,000,000	300,000,000	300,000,000	200,000,000

Equity Securities - Anti-diluti

Equity Securities - Anti-dilutive Securities (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	8,369	9,015
Underwriters
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	375	100
Warrants Issued in Connection With March 2017 Rights Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,706	1,706
Warrants Issued in Connection With February 2019 Rights Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	5,976	5,976
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	304	1,115
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	8	62
Employee Stock Purchase Plan
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)		56

Warrants - Additional Informati

Warrants - Additional Information (Details)	May 05, 2020USD ($)$ / sharesshares	Feb. 22, 2019USD ($)$ / sharesshares	Feb. 15, 2019shares	Mar. 06, 2017$ / sharesshares	Feb. 28, 2019USD ($)	Jun. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2019shares	Dec. 31, 2019USD ($)$ / shares
Right Offering [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon right offering | shares		5,976,000		1,706,000
Share price (in dollars per share)		$ 5.792		$ 11.76
Proceeds from issuance or sale of equity, total | $		$ 34,400,000			$ 34,400,000
Exercise price of exercisable warrant		$ 11.76
Underwriter warrants price per share		11.76
Additional share price (in dollars per share)		$ 11.76		$ 11.76
Term of warrants		5 years		5 years
Warrants to purchase shares of common stock | shares						632
Underwriter’s Warrants [Member]
Class Of Warrant Or Right [Line Items]
Percentage of underwriting fee and reimbursable expenses	8.50%
Underwriting fee and reimbursable expenses | $	$ 90,000
Other expenses | $	100,000
Cash consideration | $	$ 100
Purchase of common stock by underwriter granted | shares	375,000
Exercise price of exercisable warrant	$ 1.25
Warrants expiration date	Apr. 30, 2020
Underwriter warrants price per share	$ 1.25
Warrant [Member]
Class Of Warrant Or Right [Line Items]
Exercise price of exercisable warrant	$ 0.75					$ 11.27		$ 11.76
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs (in shares) | shares	280,000
Underwriter warrants price per share	$ 0.75					$ 11.27		$ 11.76
Warrants exercisable, intrinsic value | $						$ 0
Warrant [Member] | Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	5 years
Warrant [Member] | Risk Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	94
Warrant [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	0.67
Warrant [Member] | Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	0
March 2017 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants issued | shares			1.7
Adjustment to additional paid-in capital and accumulated deficit | $								$ 1,600,000
March 2017 Warrants [Member] | Right Offering [Member]
Class Of Warrant Or Right [Line Items]
Term of warrants			2 years
March 2017 Warrants Before Extension [Member] | Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			3 years 29 days
March 2017 Warrants Before Extension [Member] | Risk Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			2.50
March 2017 Warrants Before Extension [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			81
March 2017 Warrants Before Extension [Member] | Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0
March 2017 Warrants After Extension [Member] | Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			5 years 29 days
March 2017 Warrants After Extension [Member] | Risk Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			2.49
March 2017 Warrants After Extension [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			82
March 2017 Warrants After Extension [Member] | Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon right offering | shares	7,500,000
Share price (in dollars per share)	$ 1
Proceeds from issuance or sale of equity, total | $	$ 6,700,000
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs (in shares) | shares						7,500,000	5,976,000

Warrants - Summary of Warrants

Warrants - Summary of Warrants Activity (Details) - Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding at beginning	7,682,000
Issued	375,000
Outstanding at ending	8,057,000	7,682,000
Exercisable at ending	8,057,000
Class of Warrant or Right, Exercise Price of Warrants or Rights [Roll Forward]
Outstanding at beginning	$ 11.76
Issued	1.25
Outstanding at ending	11.27	$ 11.76
Exercisable at ending	$ 11.27
Class of Warrant or Right, Weighted Average Remaining Contractual Life of Warrants or Rights [Roll Forward]
Outstanding at ending	3 years 9 months 3 days	4 years 2 months 15 days
Exercisable at ending	3 years 9 months 3 days
Issued	4 years 9 months 29 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - 2011 Equity Incentive Plan - Employee Stock Option shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020$ / sharesshares	Dec. 31, 2019$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, number of shares (in shares) | shares	984
Granted, number of shares (in shares) | shares	206
Forfeited or expired, number of shares (in shares) | shares	(886)
Options outstanding, number of shares (in shares) | shares	304	984
Options exercisable, number of shares (in shares) | shares	181
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 21.78
Granted, weighted average exercise price (in dollars per share) | $ / shares	5.98
Forfeited or expired, weighted average exercise price (in dollars per share) | $ / shares	20.50
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	14.82	$ 21.78
Options exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 18.90
Options outstanding, weighted average remaining contractual life (Year)	8 years 18 days	7 years 8 months 12 days
Options exercisable, weighted average remaining contractual life (Year)	7 years 6 months 21 days

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2019
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 7 months 20 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 40,000	$ 40,000
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of stock options exercisable	0	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 700,000	$ 700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 9 months 3 days
2011 Equity Incentive Plan | Certain Employees and Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		205,701
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 5.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value		$ 800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 4.05
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		6 years 7 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		78.00%
Forfiture and expiration of stock Option	586,000	886,000
Stock or Unit Option Plan Expense	$ 88,000	$ 255,000
2011 Equity Incentive Plan | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		206,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 5.98
Forfiture and expiration of stock Option		886,000
2011 Equity Incentive Plan | Employee Stock Option | Certain Employees and Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
The 2015 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	77,031	77,031
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Repurchase and cancelation of common stock shares	39,467	39,467
Cost related to repurchase and cancelation of common stock shares		$ 270,000

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Unit (RSU) Activity (Details) - Restricted Stock Units (RSUs) shares in Thousands	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding, number of awards (in shares) | shares	61
Vested and released (in shares) | shares	(15)
Forfeited/canceled, number of awards (in shares) | shares	(38)
Outstanding, number of awards (in shares) | shares	8
Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 5.92
Vested and released, weighted average grant date fair value per share (in dollars per share) | $ / shares	5.92
Forfeited/canceled, weighted average grant date fair value per share (in dollars per share) | $ / shares	5.92
Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 5.92

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Allocated share-based compensation expense	$ 88	$ 859	$ 367	$ 1,757
Cost of Sales
Allocated share-based compensation expense		43		90
Research and Development
Allocated share-based compensation expense	7	134	109	321
Clinical and Regulatory
Allocated share-based compensation expense	12	31	27	65
Selling and Marketing
Allocated share-based compensation expense		131	41	261
General and Administrative
Allocated share-based compensation expense	$ 69	$ 520	$ 190	$ 1,020

Risk and Uncertainties - Additi

Risk and Uncertainties - Additional Information (Details)	Jun. 30, 2020Employee
Risks And Uncertainties [Abstract]
Number of retained employees	10

Litigation, Claims and Assess_2

Litigation, Claims and Assessments - Additional Information (Details) - USD ($)	Jul. 21, 2020	Jun. 23, 2020
Commitments And Contingencies [Line Items]
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net		$ 3,000,000
Subsequent Event [Member]
Commitments And Contingencies [Line Items]
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 3,000,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	Jul. 23, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Stockholders equity		$ 2,083,000	$ (1,318,000)	$ 7,275,000	$ 21,195,000	$ 28,529,000	$ 3,084,000
Subsequent Event [Member] | NASDAQ [Member]
Subsequent Event [Line Items]
Minimum market value of listed securities	$ 35,000,000
Minimum market value of listed securities violation period as per the listing rule	30 days
Income (loss) from continuing operations	$ 500,000
Period to regain compliance with NASDAQ	180 days
Description of letter from listing qalifications department	On July 23, 2020, Nasdaq notified us that we no longer met Listing Rule 5550(b)(2) (the “Rule”) requiring the Company to maintain a minimum market value of listed securities (“MVLS”) of $35 million. Nasdaq’s notice was based on a review of our MVLS for the prior 30 business days. Nasdaq’s letter also noted that we do not meet the requirements under Listing Rules 5550(b)(1) and 5550(b)(3) which require stockholders’ equity of at least $2.5 million, or net income from continuing operations of $500,000 in the most recently completed, or in two of the three most recently completed, fiscal years, respectively. However, Nasdaq’s listing rules provide us a compliance period of 180 calendar days, or until January 19, 2021, in which to regain compliance.
Description of letter of compliance	If at any time during this compliance period our MVLS closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide us written confirmation of compliance and the matter will be closed.
Subsequent Event [Member] | NASDAQ [Member] | Minimum [Member]
Subsequent Event [Line Items]
Stockholders equity	$ 2,500,000